Total Payments
$388,893
2024 Payments
$111,924
Companies
12
Transactions
578
Medicare Patients
6,593
Medicare Billing
$772,636
Payment Breakdown by Category
Other$309,153 (79.5%)
Travel$38,256 (9.8%)
Consulting$29,331 (7.5%)
Food & Beverage$12,136 (3.1%)
Education$17.18 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $306,653 | 174 | 78.9% |
| Travel and Lodging | $38,256 | 237 | 9.8% |
| Consulting Fee | $29,331 | 11 | 7.5% |
| Food and Beverage | $12,136 | 152 | 3.1% |
| Grant | $2,500 | 1 | 0.6% |
| Education | $17.18 | 3 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $183,836 | 259 | $0 (2024) |
| Alexion Pharmaceuticals, Inc. | $138,359 | 196 | $0 (2024) |
| Radius Health, Inc. | $43,540 | 70 | $0 (2024) |
| Shire North American Group Inc | $11,389 | 13 | $0 (2019) |
| Kyowa Kirin, Inc. | $8,770 | 19 | $0 (2024) |
| SANOFI-AVENTIS U.S. LLC | $2,541 | 2 | $0 (2023) |
| Abbott Laboratories | $253.99 | 13 | $0 (2024) |
| Lilly USA, LLC | $108.82 | 2 | $0 (2018) |
| Ascendis Pharma Inc | $40.60 | 1 | $0 (2023) |
| Valeant Pharmaceuticals North America LLC | $24.18 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $111,924 | 171 | Alexion Pharmaceuticals, Inc. ($98,604) |
| 2023 | $38,189 | 60 | Alexion Pharmaceuticals, Inc. ($21,398) |
| 2022 | $21,010 | 31 | Amgen Inc. ($16,678) |
| 2021 | $24,439 | 28 | Amgen Inc. ($18,195) |
| 2020 | $17,801 | 23 | Amgen Inc. ($10,552) |
| 2019 | $59,996 | 77 | Amgen Inc. ($44,225) |
| 2018 | $50,857 | 89 | Radius Health, Inc. ($24,940) |
| 2017 | $64,677 | 99 | Amgen Inc. ($52,169) |
All Payment Transactions
578 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | Amgen Inc. | EVENITY (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $600.00 | General |
| Category: Bone Health | ||||||
| 12/13/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,080.00 | General |
| Category: Rare Disease | ||||||
| 12/03/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,080.00 | General |
| Category: Rare Disease | ||||||
| 11/08/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | Cash or cash equivalent | $206.92 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 11/08/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | Cash or cash equivalent | $205.38 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 11/08/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | Cash or cash equivalent | $169.25 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 11/08/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | Cash or cash equivalent | $127.94 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 11/01/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,440.00 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 11/01/2024 | Kyowa Kirin, Inc. | — | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $765.00 | General |
| 10/31/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Travel and Lodging | Cash or cash equivalent | $206.92 | General |
| Category: Rare Disease | ||||||
| 10/30/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,880.00 | General |
| Category: Rare Disease | ||||||
| 10/30/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,080.00 | General |
| Category: Rare Disease | ||||||
| 10/30/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $114.68 | General |
| Category: Rare Disease | ||||||
| 10/30/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $18.47 | General |
| Category: Rare Disease | ||||||
| 10/29/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,880.00 | General |
| Category: Rare Disease | ||||||
| 10/29/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Travel and Lodging | In-kind items and services | $295.96 | General |
| Category: Rare Disease | ||||||
| 10/29/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Travel and Lodging | Cash or cash equivalent | $206.92 | General |
| Category: Rare Disease | ||||||
| 10/29/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Food and Beverage | In-kind items and services | $124.99 | General |
| Category: Rare Disease | ||||||
| 10/26/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | In-kind items and services | $592.94 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/25/2024 | Kyowa Kirin, Inc. | Crysvita (Drug) | Travel and Lodging | In-kind items and services | $266.96 | General |
| Category: fibroblast growth factor 23 (FGF23) blocking antibody. | ||||||
| 10/23/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Travel and Lodging | Cash or cash equivalent | $174.94 | General |
| Category: Rare Disease | ||||||
| 10/22/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,880.00 | General |
| Category: Rare Disease | ||||||
| 10/22/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Travel and Lodging | In-kind items and services | $518.96 | General |
| Category: Rare Disease | ||||||
| 10/22/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Travel and Lodging | Cash or cash equivalent | $257.97 | General |
| Category: Rare Disease | ||||||
| 10/22/2024 | Alexion Pharmaceuticals, Inc. | STRENSIQ (Biological) | Travel and Lodging | In-kind items and services | $237.89 | General |
| Category: Rare Disease | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 10 | 1,687 | 5,726 | $813,382 | $155,829 |
| 2022 | 11 | 1,639 | 5,535 | $862,972 | $148,960 |
| 2021 | 14 | 1,704 | 22,663 | $1.3M | $267,643 |
| 2020 | 15 | 1,563 | 15,981 | $1.0M | $200,204 |
Total Patients
6,593
Total Services
49,905
Medicare Billing
$772,636
Procedure Codes
50
All Medicare Procedures & Services
50 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 38 | 3,780 | $228,010 | $69,274 | 30.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 527 | 572 | $121,264 | $36,105 | 29.8% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2023 | 914 | 914 | $312,588 | $35,182 | 11.3% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 23 | 63 | $13,293 | $3,962 | 29.8% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 37 | 37 | $21,719 | $3,430 | 15.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 27 | 27 | $8,478 | $2,548 | 30.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $8,694 | $1,804 | 20.7% |
| 99221 | Initial hospital care with straightforward or low level of medical decision making, per day, if using time, at least 40 minutes | Facility | 2023 | 19 | 19 | $5,624 | $1,280 | 22.8% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2023 | 40 | 200 | $84,400 | $1,252 | 1.5% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2023 | 44 | 96 | $9,312 | $992.67 | 10.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2022 | 32 | 3,480 | $209,914 | $58,495 | 27.9% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 473 | 506 | $107,272 | $32,155 | 30.0% |
| 77080 | Dxa bone density measurement of hip, pelvis, spine | Office | 2022 | 768 | 768 | $262,656 | $29,619 | 11.3% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2022 | 74 | 74 | $43,438 | $7,705 | 17.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 60 | 60 | $18,840 | $5,525 | 29.3% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 40 | 91 | $19,201 | $5,150 | 26.8% |
| 99221 | Initial hospital inpatient care per day, typically 30 minutes | Facility | 2022 | 37 | 39 | $11,544 | $3,093 | 26.8% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 12 | 12 | $7,200 | $2,174 | 30.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 27 | 27 | $13,041 | $1,955 | 15.0% |
| J3489 | Injection, zoledronic acid, 1 mg | Office | 2022 | 76 | 380 | $160,360 | $1,945 | 1.2% |
| 96372 | Injection of drug or substance under skin or into muscle | Office | 2022 | 40 | 98 | $9,506 | $1,143 | 12.0% |
| J3111 | Injection, romosozumab-aqqg, 1 mg | Office | 2021 | 12 | 18,690 | $509,489 | $136,420 | 26.8% |
| 77080 | Bone density measurement of the core or central skeleton (e.g., hips, pelvis, spine) | Office | 2021 | 866 | 866 | $296,172 | $34,386 | 11.6% |
| J0897 | Injection, denosumab, 1 mg | Office | 2021 | 22 | 1,920 | $114,576 | $31,161 | 27.2% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 397 | 422 | $89,464 | $26,470 | 29.6% |
About Dr. Steven Petak, MD
Dr. Steven Petak, MD is a Endocrinology, Diabetes & Metabolism healthcare provider based in Houston, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/09/2005. The National Provider Identifier (NPI) number assigned to this provider is 1861493157.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Steven Petak, MD has received a total of $388,893 in payments from pharmaceutical and medical device companies, with $111,924 received in 2024. These payments were reported across 578 transactions from 12 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($306,653).
As a Medicare-enrolled provider, Petak has provided services to 6,593 Medicare beneficiaries, totaling 49,905 services with total Medicare billing of $772,636. Data is available for 4 years (2020–2023), covering 50 distinct procedure/service records.
Ad
Practice Information
- Specialty Endocrinology, Diabetes & Metabolism
- Other Specialties Diabetes & Metabolism
- Location Houston, TX
- Active Since 08/09/2005
- Last Updated 08/13/2014
- Taxonomy Code 207RE0101X
- Entity Type Individual
- NPI Number 1861493157
Products in Payments
- Prolia (Biological) $84,968
- STRENSIQ (Biological) $80,020
- EVENITY (Biological) $44,724
- Tymlos (Biological) $43,344
- NATPARA (Drug) $10,149
- Strensiq (Drug) $8,026
- Crysvita (Drug) $5,995
- NO PRODUCT DISCUSSED (Drug) $2,500
- FREESTYLE LIBRE (Device) $200.80
- FORTEO (Drug) $108.82
- Tymlos (Drug) $106.80
- FreeStyle Libre (Device) $53.19
- RELISTOR (Drug) $24.18
- Repatha (Biological) $24.07
- Ozempic (Drug) $19.51
- CUVITRU (Biological) $11.73
- Enbrel (Biological) $9.49
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Endocrinology, Diabetes & Metabolism Doctors in Houston
Dr. Rocio Harbison, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $1.1M
Endocrinology, Diabetes & Metabolism $1.1M
Dr. Andres Splenser, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $998,793
Endocrinology, Diabetes & Metabolism $998,793
Damaris Vega, Md, MD
Endocrinology, Diabetes & Metabolism — Payments: $995,666
Endocrinology, Diabetes & Metabolism $995,666
Rakesh Patel, Do, DO
Endocrinology, Diabetes & Metabolism — Payments: $435,758
Endocrinology, Diabetes & Metabolism $435,758
Dr. Veena Watwe, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $224,669
Endocrinology, Diabetes & Metabolism $224,669
Dr. Brian Tulloch, M.d, M.D
Endocrinology, Diabetes & Metabolism — Payments: $174,403
Endocrinology, Diabetes & Metabolism $174,403